email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
496 - 510
of 3630 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
Next
TandemAI Raises $35 Million for AI/WetLab Drug Discovery Operations
$5.00
Available
Immorna Raises $100 Million for Clinical Trials of Novel RNA Candidates
$5.00
Available
Atom Bioscience Says Gout Treatment Meets Phase II Efficacy/Safety Endpoints
$5.00
Available
Shanghai Oricell Raises $45 Million to Take Cellular Immunotherapies to US
$5.00
Available
Junshi Reports anti-PCSK9 mAb Lowers Cholesterol in Phase III Trials
$5.00
Available
Kelun Biotech Plans Hong Kong IPO to Develop ADCs and Other Products
$5.00
Available
Chipscreen Signs $72 Million Deal for Eucure Bispecific Immunotherapy
$5.00
Available
BeiGene’s PD-1 Approved in China for Tenth Indication, Gastric Cancer
$5.00
Available
InnoCare-Keymed JV Starts China Trial of Novel CCR8 Immunotherapy
$5.00
Available
Keymed-Lepu JV Out-Licenses Claudin 18.2 ADC to AstraZeneca in $1.2 Billion Agreement
$5.00
Available
Kinnate, a Precision Oncology Company, Pays $24 Million to Buy Out JV Partners
$5.00
Available
Shenzhen Fapon Bio Starts US Trial of CD47 mAb for Advanced Malignancies
$5.00
Available
InnoCare’s $937 Million MS Deal Falls Apart as Biogen Returns Rights
$5.00
Available
Neurophth Completes Dosing in Phase III Trial of Gene Therapy for Hereditary Blindness
$5.00
Available
Frontera Therapeutics Begins Trials for Three Leading Gene Therapy Candidates
$5.00
Available